ANDA 215861, held by Meitheal. Palonosetron Hydrochloride.
As of Nov 16, 2026, ANDA 215861 (Palonosetron Hydrochloride), held by Meitheal, was first approved by FDA on Aug 14, 2023, with 0 approved supplements and 0 published complete response letters.
Palonosetron Hydrochloride Injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 14, 2023 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Palonosetron HydrochlorideEQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) · injectable;intravenous | Palonosetron Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters